A randomised study evaluating the use of pyridoxine to avoid capecitabine dose modifications. (2012)
Attributed to:
Hub in Trials Methodology Research (MRC Biostatistics Unit, Cambridge)
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1038/bjc.2012.318
PubMed Identifier: 22814578
Publication URI: http://europepmc.org/abstract/MED/22814578
Type: Journal Article/Review
Volume: 107
Parent Publication: British journal of cancer
Issue: 4
ISSN: 0007-0920